CEP-1347 Enhances the Sensitivity of Ovarian Clear Cell Carcinoma Cells to Navitoclax by Downregulating MCL1
5 affiliations
- 1Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
- 2Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
- 3Department of Neurosurgery, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
- 4Department of Clinical Oncology, Yamagata Prefectural Shinjo Hospital, 720-1 Kanazawa, Shinjo 996-8585, Japan
- 5Department of Ophthalmology and Visual Sciences, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
Abstract
Ovarian clear cell carcinoma (OCCC) is a rare, but highly malignant subtype of epithelial ovarian cancer that is characterized by inherent chemoresistance and limited treatment options, underscoring the need for effective and novel therapeutic approaches. We previously reported the cytotoxic effects of the combination of CEP-1347, a kinase inhibitor that induces cytostatic effects by activating the p53-p21 pathway, and navitoclax in OCCC cells; however, the mechanisms underlying this sensitization remain unclear. We herein demonstrated that the CEP-1347/navitoclax combination induced cell death in OCCC cells with different TP53 gene statuses. Instead, a Western blot analysis of anti-apoptotic factors suggested that CEP-1347 sensitized OCCC cells to navitoclax by inhibiting MCL1 expression. In support of this, the downregulation of MCL1 sensitized OCCC cells to navitoclax, whereas MCL1 overexpression attenuated CEP-1347/navitoclax-induced cell death. Unlike S63845, an MCL1-targeting BH3 mimetic that sensitized normal cells as well as OCCC cells, CEP-1347 preferentially sensitized OCCC cells to navitoclax without affecting normal cells. These results suggest the potential of CEP-1347-based combination treatment, which preferentially sensitizes OCCC cells to navitoclax by downregulating MCL1, as a safer alternative to MCL1-targeted BH3 mimetics, and provide support for further investigations on this combination as a therapeutic strategy for OCCC.
Related
- METTL3-mediated m6A modification of DNMT1 enhances ovarian cancer progression
- Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer
- EBV‐Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma
- The long isoform of FABP6 facilitates WWP2-mediated PTEN ubiquitination to activate AKT/mTOR signalling and contributes to reduced everolimus sensitivity in clear cell renal cell carcinoma.
- The Gordian Knot Enhances Ubiquitin Binding in UCH-L1
BibTeX
@article{ito2026cep1347,
title = {{CEP-1347 Enhances the Sensitivity of Ovarian Clear Cell Carcinoma Cells to Navitoclax by Downregulating MCL1}},
author = {Yasufumi Ito and Yurika Nakagawa-Saito and Kazuki Nakamura and Shuhei Suzuki and Yuta Mitobe and Senri Takenouchi and Keita Togashi and Asuka Sugai and Manabu Seino and Tsuyoshi Ohta and Satoru Nagase and Chifumi Kitanaka and Masashi Okada},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209261},
url = {https://www.mdpi.com/1422-0067/27/20/9261},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CEP-1347 Enhances the Sensitivity of Ovarian Clear Cell Carcinoma Cells to Navitoclax by Downregulating MCL1
AU - Yasufumi Ito
AU - Yurika Nakagawa-Saito
AU - Kazuki Nakamura
AU - Shuhei Suzuki
AU - Yuta Mitobe
AU - Senri Takenouchi
AU - Keita Togashi
AU - Asuka Sugai
AU - Manabu Seino
AU - Tsuyoshi Ohta
AU - Satoru Nagase
AU - Chifumi Kitanaka
AU - Masashi Okada
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209261
UR - https://www.mdpi.com/1422-0067/27/20/9261
AB - Ovarian clear cell carcinoma (OCCC) is a rare, but highly malignant subtype of epithelial ovarian cancer that is characterized by inherent chemoresistance and limited treatment options, underscoring the need for effective and novel therapeutic approaches. We previously reported the cytotoxic effects of the combination of CEP-1347, a kinase inhibitor that induces cytostatic effects by activating the p53-p21 pathway, and navitoclax in OCCC cells; however, the mechanisms underlying this sensitization remain unclear. We herein demonstrated that the CEP-1347/navitoclax combination induced cell death in OCCC cells with different TP53 gene statuses. Instead, a Western blot analysis of anti-apoptotic factors suggested that CEP-1347 sensitized OCCC cells to navitoclax by inhibiting MCL1 expression. In support of this, the downregulation of MCL1 sensitized OCCC cells to navitoclax, whereas MCL1 overexpression attenuated CEP-1347/navitoclax-induced cell death. Unlike S63845, an MCL1-targeting BH3 mimetic that sensitized normal cells as well as OCCC cells, CEP-1347 preferentially sensitized OCCC cells to navitoclax without affecting normal cells. These results suggest the potential of CEP-1347-based combination treatment, which preferentially sensitizes OCCC cells to navitoclax by downregulating MCL1, as a safer alternative to MCL1-targeted BH3 mimetics, and provide support for further investigations on this combination as a therapeutic strategy for OCCC.
SN - 1422-0067
ER -